#1 Clinical Trials Search in Europe

Cebsulfase Alfa

Cebsulfase Alfa, also known as SHP611 or TAK-611, is an investigational drug being studied in clinical trials for the treatment of Late Infantile Metachromatic Leukodystrophy (MLD). This rare genetic disorder affects the nervous system and causes progressive loss of motor function. The trials aim to evaluate the safety and efficacy of intrathecal administration of Cebsulfase Alfa in children with MLD, focusing on its potential to slow down or halt the progression of the disease.

Table of Contents

What is Cebsulfase Alfa?

Cebsulfase alfa, also known by its product codes TAK-611, HGT-1110, or SHP611, is an investigational drug being developed to treat a rare genetic disorder called Late Infantile Metachromatic Leukodystrophy (MLD)[1][2]. It is a type of enzyme replacement therapy, which means it’s designed to replace a missing or malfunctioning enzyme in the body.

What is Metachromatic Leukodystrophy (MLD)?

Metachromatic Leukodystrophy is a rare genetic disorder that affects the nervous system. In MLD, a person’s body can’t produce enough of an important enzyme called arylsulfatase A (ASA). This leads to a buildup of substances called sulfatides in the brain and other parts of the body, which causes damage to the protective covering of nerve cells (myelin)[1].

The late infantile form of MLD typically starts showing symptoms between 6 months and 2 years of age. Children with this condition may lose abilities they once had, such as walking, talking, and eating[1].

How Cebsulfase Alfa Works

Cebsulfase alfa is designed to replace the missing or malfunctioning ASA enzyme in people with MLD. By providing a working version of this enzyme, the drug aims to reduce the buildup of harmful sulfatides in the body, potentially slowing down or stopping the progression of the disease[1][2].

Clinical Trials of Cebsulfase Alfa

Cebsulfase alfa is currently being studied in clinical trials to evaluate its safety and effectiveness in treating children with late infantile MLD. These trials are looking at several important aspects:

  • How the drug affects a child’s ability to move and walk[1]
  • Changes in the levels of sulfatides in the cerebrospinal fluid (the fluid surrounding the brain and spinal cord)[1]
  • How the drug affects a child’s overall motor function and ability to perform daily activities[1][2]
  • Long-term safety and effectiveness of the treatment[2]

How Cebsulfase Alfa is Administered

Cebsulfase alfa is given through a method called intrathecal administration. This means the drug is injected directly into the fluid surrounding the brain and spinal cord. To make this process easier and safer for long-term treatment, a special device called the SOPH-A-PORT Mini S is used[1][2]. This device is surgically implanted under the skin and allows for repeated doses of the medication to be given over time.

Who is Eligible for Cebsulfase Alfa Treatment?

The current clinical trials are focusing on children with late infantile MLD. Eligibility criteria include:

  • Confirmed diagnosis of MLD with low ASA enzyme activity and high sulfatide levels in urine[1]
  • Specific age ranges, typically between 6 months and 6 years old, depending on the study group[1]
  • Certain levels of motor function, as measured by specific assessment tools[1]

It’s important to note that these criteria are for the current clinical trials and may change as research progresses.

Safety Considerations

As with any medical treatment, there are potential risks and safety considerations with cebsulfase alfa. The clinical trials are closely monitoring for any side effects or adverse reactions. Some key safety aspects being evaluated include:

  • Any adverse reactions to the medication or the delivery device[1][2]
  • Changes in blood and cerebrospinal fluid tests[2]
  • Development of antibodies against the medication[2]

Future Research and Long-term Effects

While the current research on cebsulfase alfa is promising, it’s important to understand that this is still an investigational treatment. Ongoing and future studies will continue to evaluate its long-term safety and effectiveness. Researchers are particularly interested in how the treatment affects children’s motor function, adaptive behavior, and quality of life over extended periods[2].

As research progresses, we may learn more about how cebsulfase alfa could potentially help children with MLD maintain their abilities and improve their overall health and well-being.

Aspect Details
Drug Name Cebsulfase Alfa (SHP611, TAK-611)
Condition Studied Late Infantile Metachromatic Leukodystrophy (MLD)
Administration Method Intrathecal injection using SOPH-A-PORT Mini S IDDD
Primary Objective Evaluate effects on time to loss of locomotion
Secondary Objectives Assess impact on gross motor function, CSF sulfatides levels, adaptive behavior, and long-term safety
Key Inclusion Criteria Children aged 6-72 months with confirmed MLD diagnosis and specific motor function criteria
Key Exclusion Criteria History of bone marrow transplant, stem cell transplantation, or gene therapy; certain medical conditions contraindicating participation
Primary Endpoints Time to loss of locomotion, safety assessments including adverse events and laboratory tests
Secondary Endpoints Changes in gross motor function, adaptive behavior, and quality of life measures

FAQ

  • What is Cebsulfase Alfa? Cebsulfase Alfa is an investigational enzyme replacement therapy being studied for the treatment of Late Infantile Metachromatic Leukodystrophy (MLD). It is administered intrathecally, which means it is injected directly into the fluid surrounding the brain and spinal cord.
  • What is the main goal of the clinical trials using Cebsulfase Alfa? The main goal is to evaluate the effects of Cebsulfase Alfa on the time to loss of locomotion in children with late infantile MLD. Researchers are also assessing its impact on gross motor function, cerebrospinal fluid sulfatides levels, and long-term safety.
  • Who can participate in these clinical trials? The trials are primarily focused on children with Late Infantile Metachromatic Leukodystrophy. Specific age ranges and disease stages are defined for different groups in the study, ranging from 6 months to 72 months of age, depending on the group.
  • How is Cebsulfase Alfa administered in the trials? Cebsulfase Alfa is administered intrathecally using a device called SOPH-A-PORT Mini S IDDD. This device is implanted to allow long-term, intermittent access to the intrathecal space for drug delivery.
  • What are the potential benefits of participating in these trials? Participants may benefit from potential improvements in motor function or slowing of disease progression. The trials also contribute to the advancement of knowledge about MLD treatment, which could help future patients. However, it's important to note that as with any clinical trial, there are also potential risks involved.

Ongoing Clinical Trials on Cebsulfase Alfa

  • Study of Intrathecal Cebsulfase Alfa for Children with Late Infantile Metachromatic Leukodystrophy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy Spain

  • Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy

Glossary

  • Metachromatic Leukodystrophy (MLD): A rare genetic disorder that affects the nervous system. It causes a progressive loss of motor and cognitive functions due to the breakdown of the protective covering (myelin) around nerve cells.
  • Intrathecal: Refers to the space under the arachnoid membrane of the brain or spinal cord. In these trials, it means the medication is injected directly into the fluid surrounding the brain and spinal cord.
  • Enzyme Replacement Therapy: A treatment approach where a missing or deficient enzyme is replaced with a functional version to help manage symptoms of certain genetic disorders.
  • GMFC-MLD: Gross Motor Function Classification in Metachromatic Leukodystrophy. It's a system used to categorize the level of motor function in patients with MLD.
  • Cerebrospinal Fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, providing protection and helping to remove waste products.
  • Sulfatides: A type of fat (lipid) that accumulates in the nervous system of patients with MLD due to the lack of an enzyme that breaks them down.
  • SOPH-A-PORT Mini S IDDD: A medical device implanted under the skin to allow repeated delivery of medication into the intrathecal space.
  • Pharmacodynamic (PD) Biomarker: A biological indicator used to measure the effect of a drug on the body, in this case, the levels of sulfatides in the cerebrospinal fluid.
  • GMFM-88: Gross Motor Function Measure-88, a clinical test used to evaluate changes in gross motor function over time.

References

  1. http://clinicaltrials.eu/trial/study-of-intrathecal-cebsulfase-alfa-for-children-with-late-infantile-metachromatic-leukodystrophy/
  2. http://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-cebsulfase-alfa-for-children-with-late-metachromatic-leukodystrophy-receiving-intrathecal-enzyme-replacement/